Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: Objective responses and clinical outcomes.-Reference-Cited by-同舟云学术

Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: Objective responses and clinical outcomes.

Published:2011-05-20 Issue:15_suppl Volume:29 Page:5520-5520
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

William Junior W. N.,Weber R. S.,Lee J. J.,Myers J.,Ginsberg L. E.,El-Naggar A. K.,Sturgis E. M.,Sabichi A. L.,Kies M. S.,Hanna E. Y.,Hessel A. C.,Lu C.,Lai S. Y.,Ayuste R.,Lippman S. M.,Kim E. S.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2011.29.15_suppl.5520

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status;Frontiers in Oncology;2022-08-30

2. Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection;Clinical Cancer Research;2022-04-20

3. How to Achieve Therapeutic Response in Erlotinib-Resistant Head and Neck Squamous Cell Carcinoma? New Insights from Stable Isotope Labeling with Amino Acids in Cell Culture-Based Quantitative Tyrosine Phosphoproteomics;OMICS: A Journal of Integrative Biology;2021-09-01

4. MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma;Scientific Reports;2019-12

5. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy;Cochrane Database of Systematic Reviews;2015-12-01